Broker influence is growing while employers want fewer chronic-condition vendors.
Benefits leaders need support around GLP-1 use, while finance leaders need evidence they can defend.
Who you’d be doing this for
“My broker keeps asking which vendor we can actually stand behind, and I need an answer before planning starts.”
Beatriz Ramirez · Population Health Manager
Owns chronic-condition program performance and benefits access for a large employer population.
What is at stake
Employers want GLP-1 support but are consolidating chronic-condition vendors. You must weigh a focused broker package against the proof and flexibility buyers need.
Why it isn’t already fixed
Every obvious fix costs something else. That’s the part you’d have to decide.
- broker credibility vs. commercial differentiation
- GLP-1 urgency vs. clinical precision
- qualified access vs. broad reach
- employer flexibility vs. defensible economics
Why Omada Health
The Omada Platform reaches employer populations through the consultant and broker channel while its cardiometabolic offerings evolve around GLP-1 care.
Written with these in mind
Not your kind of problem? 7 more at Omada Health, or browse every organization.
This is the setup. The work is inside.
Running it puts you in the room: the full situation and its constraints, stakeholders who push back in their own words, and the decisions that are yours to make. What you produce becomes a Day One Plan — work you can show someone instead of describing.